A combined therapeutic strategy aims to improve disease control in advanced hormone‑sensitive prostate cancer

MEDSIR has presented at the ASCO scientific congress, held in Chicago, the final results of its ZZ‑FIRST study, which support the potential of combining enzalutamide and talazoparib in high‑volume metastatic hormone‑sensitive prostate cancer. The study, which enrolled 54 patients from...